Sitala Bio
Develops medicines targeting harmful inflammation for patients with neurodegenerative and inflammatory diseases
Highlights
- New on EvolcAdded 2026-11-01
About Sitala Bio
Sitala Bio develops medicines intended to block harmful inflammation, targeting neurodegenerative diseases such as Parkinson’s and Alzheimer’s, as well as inflammatory diseases affecting the body.
The company is based in Cambridge, England, and was founded in 2021.
Product: Medicines targeting harmful inflammation in neurodegenerative and inflammatory diseases.
Jobs at Sitala Bio
More biotech & pharma companies
Smartway Pharmaceuticals
Pharmaceutical wholesaling and specialist medicine supply for healthcare providers, pharmaceutical companies and aid organizationsNew on EvolcSolasta Bio
Develops peptide-based precision insecticides for growers and agricultural businesses seeking crop protectionNew on EvolcSPT Labtech
Lab automation instruments for liquid handling and sample management, sold to life science research laboratoriesSpur Therapeutics
Develops gene therapies for people with chronic and debilitating diseasesNew on EvolcSpybiotech
Develops vaccines against infectious diseases and cancer using its SpyTag/SpyCatcher protein superglue platformNew on EvolcSterling Pharma Solutions
Develops and manufactures active pharmaceutical ingredients for biotech and pharmaceutical companiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.